Abbreviations & Acronyms AC = adjuvant chemotherapy BCa = bladder cancer CSS = cancer-specific survival GC = gemcitabine and cisplatin MVAC = methotrexate, vinblastine, doxorubicin and cisplatin NAC = neoadjuvant chemotherapy OS = overall survival RC = radical cystectomy RCT = randomized controlled trial Objectives: To evaluate the clinical benefit of adjuvant platinum-based chemotherapy after radical cystectomy for muscle-invasive bladder cancer in routine clinical practice. Methods: The present observational study was carried out to compare the effectiveness of adjuvant chemotherapy versus observation post-radical cystectomy in patients with clinically muscle-invasive bladder cancer. Cancer-specific survival and overall survival between the adjuvant chemotherapy group and radical cystectomy alone group were compared using Kaplan-Meier method and log-rank test. After adjusting for background factors using propensity score weighting, differences in cancer-specific survival and overall survival between these two groups were compared. Subgroup analyses by the pathological characteristics were carried out. Results: In total, 322 patients were included in the present study. Of these, 23% received adjuvant chemotherapy post-radical cystectomy. Clinicopathological characteristics showed that patients in the adjuvant chemotherapy group were pathologically more advanced and were at higher risk than the radical cystectomy alone group. In the unadjusted population, although it is not significant, the adjuvant chemotherapy group had lower overall survival (3-year overall survival; 61.5% vs 73.6%, HR 1.33, P = 0.243, log-rank test, adjuvant chemotherapy vs radical cystectomy alone). In the weighted propensity score analysis, although it is not significant, the adjuvant chemotherapy group were superior to radical cystectomy alone groups (overall survival: HR 0.65, 95% CI 0.39-1.09, P = 0.099, log-rank test, adjuvant chemotherapy vs radical cystectomy alone). Subgroup analyses showed that adjuvant chemotherapy significantly reduced the hazard ratio of overall survival and cancer-specific survival in the ≥pT3, pN+, ly+ and v+ subgroups. Conclusions: Platinum-based adjuvant chemotherapy might be associated with increased cancer-specific survival and overall survival in patients with high-risk invasive bladder cancer.
Introduction
Even after decades of research into early diagnosis and surgery modification, cancer-specific survival of RC for patients with muscle-invasive bladder cancer is still unsatisfactory, as metastatic recurrence occurs in approximately 50% of the patients. 1 To improve the outcomes with surgery alone, perioperative chemotherapy has been integrated. The European Association of Urology guidelines provides NAC grade A recommendation for muscle-invasive BCa because of its survival benefit. 2 Nevertheless, NAC remains substantially underutilized in routine clinical practice. [3] [4] [5] [6] In contrast, platinum-based AC, which is not highly recommended 1 because recent randomized clinical trials to evaluate AC in patients with locally-advanced BCa had poor accrual rates, [7] [8] [9] is used considerably more than NAC. 10 Platinum-based combination chemotherapy is the gold standard chemotherapy regimen for metastatic bladder cancer. Maase et al. reported that the efficacy of a GC regimen was not inferior to a MVAC regimen for advanced or metastatic bladder cancer. 10, 11 In the neoadjuvant setting, it was also reported that there was no difference in the rate of achieving pT0N0 between MVAC and GC. 12, 13 GC regimen has come to be used in various settings. In contrast, the evidence for AC is insufficient.
In the clinical situation where RCTs are difficult to carry out, propensity score-adjusted analysis are introduced as a statistical method to obtain clinical evidence from observational data. Propensity score-adjusted analysis is utilized to estimate the effect of a treatment by accounting for the covariates that predict receiving the treatment, and to reduce the bias as a result of confounding variables that could be found in an estimate of the treatment effect.
14 Now propensity score-adjusted analysis has become the standard statistical method to analyze observational studies. 15 To solve the conflicting situation, we here aimed to assess whether adjuvant platinum-based chemotherapy after RC for muscle-invasive BCa in routine clinical practice is beneficial, through this method.
Methods

Study population
The clinical and pathological records of patients who received RC for muscle-invasive BCa between January 2004 and December 2013 from six hospitals (Juntendo University Hospital, Juntendo-Nerima Hospital, Juntendo-Urayasu Hospital, Juntendo-Shizuoka Hospital and Teikyo University Hospital) were reviewed. Information regarding patients' demographics and tumor characteristics were obtained from the patients' medical chart. Patients who had histologically confirmed cT2 through cT4aN0M0 without distant metastasis through computed tomography, magnetic resonance imaging and bone scintigram were included in the present study. No age limit was applied. All tumors were staged according to the American Joint Committee of Cancer staging manual, 7th edition. 16 Dissection of pelvic lymph nodes including external iliac, internal iliac and obturator lymph nodes was routinely carried out. Variant histologies were included provided that urothelial carcinoma was the predominant histology.
Patient records had complete data on age (continuous variable), sex, local tumor stage, lymph nodes status (positive vs negative), type of urinary diversion, any neoadjuvant chemotherapy (yes vs no), adjuvant cisplatin-based chemotherapy (yes vs no), venous invasion (yes vs no) and lymphatic duct invasion (yes vs no). The median age was 69 years, and median follow up of the censored patients was 21.3 months (interquartile range 10.0-48.2 months). Patients whose follow up was shorter than 3 months were excluded. 
Statistical analysis
Patients' characteristics (age, sex, NAC, type of urinary diversion, pathological T category, lymph node metastasis, venous invasion, lymph duct invasion) were compared between the AC and RC alone groups using the t-test, Wilcoxon test or v 2 -test, as appropriate. CSS was defined as time from RC to date of death as a result of cancer, or censored at the date of last follow up/death as a result of other causes. OS was defined as time from RC to date of death as a result of any causes, or censored at the date of last follow-up. The survival probability between two groups was calculated by the Kaplan-Meier method, and compared by the log-rank test. To identify significant prognosticators, uni-and multivariate analyses were carried out using a Cox proportional hazards model. In the multivariate analyses, we set the presence of AC in addition to the variables that were significant in the univariate analyses.
The differences in the background clinicopathological characteristics between the two groups were adjusted through propensity score weighting. 17 To approximate the patients' characteristics of the RC alone group to that of the AC group, we carried out weighting analyses with weight one for patients in the AC group and {propensity score / (1-propensity score)} for patients in the RC alone group. 18 The propensity score for each patient was estimated by a logistic regression model using two groups as dependent variables, and all patients' characteristics as independent variables. Propensity score was estimated by seven clinicopathological characteristics (age, gender, existence of NAC, pathological T categories, lymph node metastasis, venous invasion and lymph duct invasion). Adjusted survival probabilities between the two groups were calculated by the Kaplan-Meier methods, and compared by the log-rank test using the sandwich variance estimator. 19 In the propensity score-adjusted population, subgroup analyses for each pathological characteristic were carried out. The present study was approved by the institutional review board , and registered with the University Hospital Medical Information Network Clinical Trials (UMIN00002180).
Results
We identified 379 patients who received RC. Of these, 322 patients (AC 74, RC alone 248 patients) without missing data were included in the analysis. In the clinical T2 bladder cancer, three patients who had a second transurethral resection of bladder tumor carried out were included. One of the three patients had an upgrading from T1 in initial transurethral resection of bladder tumor. Table 1 shows patients' characteristics and clinicopathological data in the AC and RC alone groups. Patients in the AC group were significantly more advanced, and were at higher risk than the RC alone group in the pathological T stage, lymph nodes metastasis, venous invasion and lymphatic duct invasion.
Patient characteristics and clinicopathological data
In the AC group, seven cases (9.5%) were on the MVAC regimen and 67 cases (90.5%) were on the GC regimen. Two courses of MVAC were carried out on all cases. Two courses of GC were carried out on 62 cases (92.5%), and three courses of GC were carried out on the rest (7.5%). In each group, approximately 10% of the cases had NAC (AC, 10 cases [13.5%]; RC alone, 25 cases [10.1%] ). In the NAC, seven cases (20.0%) were on the MVAC regimen (AC, three cases; RC alone, four cases) and 28 cases (80.0%) were on the GC regimen (AC, seven cases; RC alone, 21 cases). A total of 14 cases (40.0%) had one course (AC, five cases; RC alone, nine cases), and 21 cases (60.0%) had two courses (AC, five cases; RC alone, 16 cases).
In terms of clinical and pathological factors, age, pathological T category, frequency of lymph node metastasis, venous invasion, and lymphatic duct invasion were significantly different between the AC group and the RC alone group (Table 1) . Patients in the RC alone group were older than the AC group. The AC group had more pT3 disease, positive lymph node metastasis, venous invasion or lymphatic duct invasion.
Univariate and multivariate analysis
In the unadjusted analysis, the AC group had higher BCaspecific mortality and overall mortality (3-year CSS 64.2% vs 77.0%, HR 1.49, P = 0.121, log-rank test; 3-year OS 61.5% vs 73.6%, HR 1.33, P = 0.243, log-rank test, AC vs RC alone, respectively; Fig. 1 ). Cancer-specific mortality and overall mortality were 26 cases (37.7%) and 24 cases (34.8%) in AC group, and 47 cases (18.6%) and 59 cases (23.3%) in RC alone group, respectively. Univariate analysis using Cox proportional hazards model showed that T categories, lymph node metastasis, venous invasion and lymphatic duct invasion were significantly associated with mortality risk, although AC was not associated with either CSS or OS (Table 2) . NAC was not associated with BCaspecific and overall mortality. In the multivariate analysis after adjusting for multiple confounding factors, AC had lower overall and BCa-specific mortality risks ( Table 2 ). The presence of lymph node metastasis was significantly associated with increased overall and BCa-specific mortality risks ( Table 2) .
Weighted propensity score survival analysis
As the AC group had more advanced and high-risk disease, patient numbers in each background factor were adjusted by weighted propensity score for the survival analyses. After analysis by weighted propensity score, confounding factors were no longer different between the two groups ( Table 1) . CSS tended to be longer in the AC group than the RC alone group (2 years 70.4% vs 58.3%; 3 years 64.2% vs 52.5%, AC vs RC alone, respectively), although it was not statistically significant (CSS HR 0.65, 95% CI 0.38-1.12, P = 0.12, log-rank test; Fig. 2a) . Similarly, OS tended to be longer in the AC group than the RC alone group (2 years 69.5% vs 55.6%; 3 years 61.5% vs 49.3%, AC vs RC alone, respectively), although it was not statistically significant (OS HR 0.65, 95% CI 0.39-1.09, P = 0.099, log-rank test; Fig. 2b ). Table 3 shows the subgroup analyses for CSS and OS between two groups in the propensity score-adjusted population. In patients with either pathological stage >pT3, the presence of lymph node metastasis, venous invasion and lymphatic duct invasion, AC was significantly associated with increased CSS and OS. Furthermore, patients who were older and men were more likely to have beneficial OS with AC.
Discussion
The clinical evidence of AC is less robust than NAC. However, several surveys suggest that urologists prefer to use AC more frequently than NAC. [4] [5] [6] Physicians might prefer AC, as it is carried out based on accurate pathological staging, potentially limiting its toxic effects in high-risk patients who are most likely to benefit from the treatment, and averting delays in possibly curative surgery. 3 AC might be beneficial to suppress the micrometastasis during surgery, which can lead to distant metastasis or local recurrence. 20 A recent meta-analysis of RCTs on AC for muscle-invasive BCa found that AC significantly reduced the mortality risk by 23%, and disease-free survival by 34%. This disease-free survival benefit was more apparent among those with positive lymph nodes. 4 A major limitation of RCTs is the strict criteria for inclusion into RCTs, which means that the patients are "idealized." Therefore, observational studies provide real-world comparative effectiveness data. Santos et al. reported the population-based retrospective cohort study to predict the costs associated with RC for BCa. 21 Naturally, they could not carry out a study analyzing predictors of costs associated with BCa unless they used a retrospective study. In the clinical situation where RCTs are difficult to carry out, propensity score-adjusted analysis is introduced as a statistical method to obtain clinical evidence from observational data. This propensity score-adjusted analysis has been shown to be useful to control for confounding variables when exploring the association between AC and survival. The propensity score is the probability that a patient receives AC, and it is modeled with observed confounding variables using the logistic regression model. Two recent observational studies in large cohorts utilized propensity score-adjusted analysis. The first, a study of a population-based cohort in Ontario, Canada, in which the majority of the patients had a high stage (T3/4; 71%), showed that AC was associated with improved CSS (HR 0.74, 95% CI 0.64-0.85) and OS (HR 0.70, 95% CI 0.62-0.80). 5 In the other study, which was from the National Cancer Database of the USA, AC improved OS (HR 0.70, 95% CI 0.64-0.76) in patients with pathological T3-4 and/or pathological node-positive disease. 22 These findings would support physicians in recommending AC for patients based on the pathological findings with RC.
In the present study, the fact that the AC group had more advanced and high-risk disease than the RC alone reflected our routine clinical practice. Weighted propensity score analysis showed that platinum-based AC was beneficial for patients with any of the risk factors for mortality (pathological stage ≥pT3, presence of lymph node metastasis, venous invasion and lymphatic duct invasion). Of note was the survival benefit for male patients with AC. Although NAC has a grade A recommendation for improving survival after RC, for patients who did not receive NAC or whose pathology of RC showed high risks for recurrence and metastasis, the present results would also support the use of AC.
The present study had several limitations. It was carried out retrospectively in multiple centers, and the number of patients enrolled was smaller than other studies. In addition, the RC operations were carried out by many surgeons. No unified policy for the clinical decision of introducing AC were set among the institutions. The regimens of AC were the mixture of MVAC and GC. NAC is now the standard treatment for muscle-invasive BCa. As the present study included patients who were treated before NAC was established, just 10% of the population received NAC. The frequency of patients who received NAC was similar between the AC group and RC alone group (Table 1) . Therefore, by taking advantage of propensity score analysis, we included patients who received NAC. Inclusion of more factors, such as social background and comorbidities, could produce different results. Other confounders might have also influenced the results. Investigations in larger cohorts that include many variables are warranted to improve our evidence.
In conclusion, after adjusting for confounders in a real clinical setting by propensity score weighting, adjuvant cisplatin-based chemotherapy was associated with increased overall and BCa-specific survival in patients who had any of the risk factors for BCa-specific mortality (pathological stage ≥pT3, presence of lymph node metastasis, venous invasion and lymphatic duct invasion).
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